Send us Feedback

Sanofi-Aventis SA (SNY)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

SNY » Topics » Amaryl

This excerpt taken from the SNY 6-K filed Jan 30, 2006.
Amaryl® has been facing competition from generics in the United States, resulting in a fall of 28.6% in net sales of the product during the period (with US sales down 86.2%) . An authorized generic version of Amaryl® was launched by Prasco Laboratories at the start of the fourth quarter, and accounted for 29.6% of glimepiride prescriptions in December 2005.

 

 

8/15


Recent events 

November 10, 2005  Sanofi Pasteur announces a contract with the French government to produce apandemic influenza vaccine 
 
November 16, 2005  Publication of results of the RIO-Lipids study in the New England Journal of Medicine 
 
December 2, 2005  Granting of a priority review for Taxotere® for a supplemental new drug application in a new indication: advanced gastric cancer 
 
December 8, 2005  Announcement of the results from the first interim efficacy analysis and updated safety analyses from the BCIRG 006 Phase III breast cancer study (Taxotere® combined with analyses from the BCIRG 006 Phase III breast cancer study (Taxotere® combined with Herceptin® ) 
 
December 15, 2005  Sanofi Pasteur announces preliminary trial results for the first vaccine candidate with adjuvant for the pre-pandemic H5N1 influenza strain, demonstrating a good immune response in a significant number of volunteers 
 
December 22, 2005  Extension of the collaboration between sanofi-aventis and Regeneron Pharmaceuticals in the (VEGF) TRAP program 
 
January 11, 2006  The FDA issues a Written Request for pediatric studies on Ambien® 
 
January 13, 2006  Pfizer purchases sanofi-aventis’ rights to Exubera® under the change of control clause for $1.3 billion 
 
January 18, 2006  Granting by the FDA of a priority review for Plavix® for a supplemental new drug application in a new indication: acute phase myocardial infarction
 
January 24, 2006  Announcement of the approval of Plavix® in Japan for reduction of recurrence in stroke victims; the product is due to be launched in Japan in the second quarter of 2006 
 
January 24, 2006  Approval of Apotex’s ANDA for clopidogrel. Clopidogrel bisulfate continues to be protected by a valid patent. The patent trial is scheduled to begin on April 3, 2006. Sanofi-aventis will vigorously defend its rights 
   
Financial Calendar  
   
February 24, 2006  2005 Full-Year Results – Analyst/Investor Meeting in Paris 
   
March 22, 2006  Analyst/Investor Meeting in New York 
   
May 5, 2006  1st Quarter 2006 Sales and Results 
   
May 31, 2006  Annual General Meeting 
   
August 2, 2006  2nd Quarter and 1st Half 2006 Sales and Results 
   
September 19, 2006  Analyst/Investor Meeting in Paris 
   
September 27, 2006  Analyst/Investor Meeting in New York 
   
October 31, 2006  3rd Quarter 2006 Sales and Results 

 


9/15

This excerpt taken from the SNY 6-K filed Nov 8, 2005.
Amaryl®

Third-quarter net sales of Amaryl® were €195 million, up 19.6% . Net sales rose by 33.6% in the United States (to €63 million), and by 10.0% in Europe (to €68 million).

In the 9 months to end September, net sales of Amaryl® advanced by 18.9% in the United States (to €172 million). In Europe, the product achieved growth of 11.1%, to €195 million. In early October, Prasco Laboratories launched an authorized generic of Amaryl® in the United States.

Internal Medicine

EXCERPTS ON THIS PAGE:

6-K
Jan 30, 2006
6-K
Nov 8, 2005

RELATED TOPICS for SNY:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki